The purpose of this study is to evaluate the safety and effectiveness of various doses of an investigational drug called ABT-888 when given with carboplatin and gemcitabine in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, especially those experiencing their first recurrence.
ABT-888 kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer drugs. It can also work well in cancer cells that do not have functional BRCA, a protein which helps to fix DNA damage. About 10 percent of ovarian cancer patients have an inherited defect in BRCA.
Carboplatin and gemcitabine are used routinely to treat these cancers. ABT-888 may make the carboplatin/gemcitabine treatment work more effectively.